WATERTOWN, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine also noted that initial readouts for its Phase 2 trial of DISC-3405 in polycythemia vera and Phase 1b trial of the same drug in sickle cell disease are expected in 2026. The ASH ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results